Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Esperion Theraper Form 4	utics, Inc.										
January 05, 2016 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								Sind3235-0287Number:January 31Expires:2005Estimated averageburden hours perresponse0.5			
<i>See</i> Instruction 1(b).		30(h)	of the Ir	ivestment	t Compar	ny Act of 1	940				
(Print or Type Respon		D *					5 Del ci di	(Danasii D			
1. Name and Address Lalwani Narendra	2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR				5. Relationship of Reporting Person(s) to Issuer						
(Last) (1 C/O ESPERION INC., 3891 RAN(SUITE 150	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2016				(Check all applicable) Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Operating Officer						
				endment, D nth/Day/Yea	-	ıl	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
	State)	(Zip)	Tab	la I. Nam I	D	C	Person	of ou Dou officio	Use Osera d		
1.Title of 2. Trai	nsaction Date h/Day/Year)	2A. Deemo	ed Date, if	3. Transactio Code	4. Securit mAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report on	a separate line	e for each cl	ass of sect	urities bene	Perso inform requir	ns who res nation cont red to respo ays a curre	or indirectly. spond to the colle ained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible s	Beneficially Owned securities)	1			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	f 8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

1

Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Security (Instr. 3)	•		y Ionth/Day/Year)	Code (Instr. 8)	Securities (Month/Da Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		n/Day/	(Instr. 3 and 4)		4)
				Code V	(A) (J	D) Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 21.65	01/04/2016		А	15,000	<u>(</u>	<u>1)</u>	01/04/2026	Common Stock	15,000
Reporting Owners										
Reporting Owner Name / Address				Relationship	s					
		Director 1	0% Owner	Officer			Other			
Lalwani Narendra D. C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108				Chief Operating Officer						
Signa	tures									
/s/ Richard B. Bartram, by power of attorney		01/0	05/2016							
**Signature of Reporting Person			Date							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 4, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.